Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| H2020:161 | Other Identifier | University of Manitoba |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Bill and Melinda Gates Foundation | OTHER |
| Stanford University | OTHER |
| The University of Western Australia | OTHER |
| University of Idaho |
Not provided
Not provided
Not provided
Not provided
The IMiC Consortium will analyze milk from 1000 mother-infant dyads across 4 diverse settings (Tanzania, Pakistan, Burkina Faso and Canada). Samples will be stored centrally at the Manitoba Interdisciplinary Lactation Centre (MILC) biorepository and distributed to multiple laboratories for analysis of macronutrients, micronutrients, oligosaccharides, growth factors, immunoglobulins, cytokines, metabolites and microbes. Data will be harmonized and stored in a central database, and diverse statistical methods will be applied for data integration and analysis.
Human Milk Composition: Milk is a highly complex biofluid that has evolved over millions of years to nourish infants and protect them from infection while their immune system matures. In addition to delivering complete nutrition (i.e. macronutrients and micronutrients), milk provides bioactive components that further support infant growth, development and health. These include immunoglobulins, antibodies, hormones, growth factors, prebiotic oligosaccharides, and probiotic bacteria. Milk composition is specifically adapted to each mammalian species depending on the growth requirements of their young offspring. For example, the average energy content of human milk is around 70 kcal/100g, compared to 38 kcal/100g in donkey milk and 171 kcal/100g in mouse milk. Mice produce just 2 milk oligosaccharides, while humans produce over 150. Even among humans, milk composition is highly variable - for example, energy content can range from 57-83 kcal/100g and oligosaccharide concentrations range from 5-25 g/L.
Surprisingly little is known about the determinants and consequences of this variation. The investigators will study the following milk components in the IMiC Consortium to understand variability between individual women and across different geographic settings, and their associations with infant growth. In addition, to guide these analyses, a review of human milk components and infant growth will be undertaken by the IMiC members during Year 1 of the Project.
Priority Components (to be analyzed in all samples):
Macronutrients include carbohydrates (primarily lactose), proteins and lipids. Lipids provide about 50% of the energy content in human milk. The vast majority (98%) of milk lipids are triacylglycerides, with the remainder consisting of diacylglycerides, monoacylglycerides, free fatty acids, phospholipids and cholesterol. The fatty acid profile of human milk varies in relation to maternal diet and genetics, particularly in the long-chain polyunsaturated fatty acids (LCPUFAs), such as arachidonic and docosahexaenoic acids, which contribute to immune function and neurodevelopment.
Micronutrient quality and concentrations can be compromised by maternal malnutrition. Micronutrients in milk include minerals (e.g. Zinc, Calcium, Phosphorus, Magnesium, Iodine, Selenium) and vitamins (A, B1, B2, B6, B12, C, D, E; folate, choline).
Immunoglobulins (Ig) are transferred in human milk, including IgA, IgM and IgG. Infants are born with immature adaptive immunity, and rely on these maternal antibodies for defense against pathogens. Soluble IgA (sIgA) is the predominant antibody of human milk; sIgA-antigen complexes are taken up by intestinal dendritic cells, allowing for antigen recognition.
Cytokines are multifunctional peptides can cross the intestinal barrier, where they influence immune activity. Milk-borne cytokines include anti-inflammatory transforming growth factor (TGF)-b, interleukins (IL)-10 and IL-7, and proinflammatory tumor necrosis factor (TNF)-a, IL-6, IL-8, and interferon (IFN)-g.
Lactoferrin is an iron binding glycoprotein with antimicrobial activity against many bacteria, viruses, and fungi. Osteopontin is an extensively phosphorylated acidic glycoprotein that is present at high concentrations in human milk. It affects immune functions, intestinal development, and brain development.
Growth factors and hormones in human milk have wide-ranging effects on the infant intestinal tract, vasculature, nervous system, and endocrine system. Some act locally on the neonatal intestine and many are absorbed into systemic circulation through the 'leaky' infant gut. Epidermal growth factor (EGF) is critical to the maturation and healing of the intestinal mucosa. Insulin-like growth factor (IGF) promotes tissue growth. The metabolic hormones leptin, insulin, adiponectin and ghrelin regulate energy conservation, appetite and infant BMI.
Human milk oligosaccharides (HMOs) are the third most abundant component of human milk. Over 100 different HMOs have been identified. These structurally diverse carbohydrates are not digested by the infant, but are metabolized by the infant's gut bacteria, providing a selective substrate to help shape the developing microbiome. In addition, HMOs serve as soluble decoy receptors and prevent pathogen attachment to infant mucosal surfaces, lowering the risk for viral and bacterial infections. HMOs may also modulate epithelial and immune cell responses and provide the infant with sialic acid, an important nutrient for brain development. In the CHILD cohort the investigators have observed that, beyond genetic secretor status, HMO composition is associated with ethnicity, lactation stage, parity, geographic location, season of collection, and breastfeeding exclusivity.
Omics approaches will be applied to broadly assess the complete spectrum of peptides, proteins, lipids, and metabolites in human milk. Targeted metabolomics analyses to be conducted using the Biocrates platform (~500 metabolites), untargeted metabolomic analyses to be conducted by Sapient Bioanalytics via mass spectrometry.
Microbes are present in human milk. Culture-dependent and independent (sequencing-based) studies have confirmed the presence of bacteria and fungi in milk from healthy mothers. In the CHILD cohort, the investigators have found that milk microbiota composition differs by infant sex, method of feeding, maternal BMI, and maternal atopy. It is estimated that breastfed infants receive 10^4-10^6 bacteria per day, providing a source of live microbes to seed the infant gut, oral cavity and airways. Studies demonstrating strain similarities between maternal gut, milk, and infant gut support this hypothesis, and find that Bifidobacterium spp. constitute the majority of shared taxa between maternal milk and infant stool. Given the central role of the gut microbiome in infant growth, metabolism and protection from infectious disease, including in low to middle income (LMIC) settings, it is critical to understand the origins of these fundamentally important gut microbes early in life.
A secondary objective of IMiC will be to support data integration across sites to answer important questions related to 1) the impact of maternal health and nutrition interventions on breast milk composition, and 2) its relation to infant health, growth and development. Each site will own its own data and will also be independently addressing these same questions by site, as originally intended in their own grants/studies.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Canadian Healthy Infant Longitudinal Development (CHILD) Cohort Study | The CHILD Cohort Study is a prospective longitudinal birth cohort study. It is an observational study of healthy term infants in Canada (Vancouver, Edmonton, Manitoba, Toronto). The birth years were between 2009-2012, and is currently at the 8 year postnatal follow up phase. IMiC will receive 400 breast milk samples from 400 dyads (100/site) that were taken between 3-4 months postnatal. | ||
| The Early Life Interventions for Childhood Growth and Development in Tanzania (ELICIT) Study | (NCT03268902). ELICIT is a randomized controlled trial (RCT) evaluating the efficacy of antimicrobials and nicotinamide in increasing growth in the setting of Rural Tanzania. It is factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis to infants. IMiC will receive 400 breast milk samples from 200 dyads, 2 samples per dyad taken at 1 & 5 months postnatal. |
| |
| VITAL Pakistan | Two Randomized Controlled Trials: Mumta (Nutritional support for lactating women with or without azithromycin)PW - NCT04012177 and MumtaLW - NCT03564652 VITAL is a community-based, randomized control, assessor blinded trial in peri-urban settings of Karachi, Pakistan to study the impact of Lipid-based Nutritional Supplement for Pregnant and Lactating women which is balanced energy-protein (BEP) dietary supplement, a locally produced ready-to-use nutritional product for lactating women (LW) and single prophylaxis dose of Azithromycin for infants, on growth of infants over the period of six months since birth compared to current standard of care. IMiC will receive 600 breast milk samples from 200 dyads, 3 samples per dyad taken at 0-1, 1-2 & 2-3 months. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vitamin B3 | Dietary Supplement | ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Create an international consortium of 4 birth cohorts in Tanzania, Pakistan, Burkina Faso and Canada (Field Site Partners), human milk scientists (Laboratory Partners), and data scientists and biostatisticians (Data Science Partners). | The result of this outcome will be measured by the completion of governance structure and data sharing agreements with all partners. | This outcome is anticipated to reach completion in December 2021. |
| Create a centralized biorepository of human milk samples from the Field Site Partners, housed at the Manitoba Interdisciplinary Lactation Centre (MILC) at the University of Manitoba in Winnipeg, Manitoba, Canada. | The result of this outcome will be measured by the completion of all milk samples collected, stored and catalogued at MILC. | This outcome is anticipated to reach completion in April 2022. |
| Create a standardized protocol for the comprehensive analysis of human milk composition using state-of-the-art methods in expert laboratories | The result of this outcome will be measured by the completion of list of target milk components; agreements with laboratories; standard operating procedures (SOPs) for sample collection, processing, shipping and analysis. | This outcome is anticipated to reach completion in December 2021. |
| Create a harmonized dataset of human milk composition and relevant maternal, infant and environmental data from 1000 dyads | The result of this outcome will be measured by complete, clean, accessible, dataset meeting FAIR (Findable, Accessible, Interoperable, Reusable: www.gofair.org) Guiding Principles, including milk composition data and relevant metadata for all included dyads. | This outcome is anticipated to reach completion in October 2023. |
| Create an integrated analysis of this dataset |
| Measure | Description | Time Frame |
|---|---|---|
| A secondary objective of IMiC will be to support data integration across sites to answer important questions. | A secondary objective of IMiC will be to support data integration across sites to answer important questions related to 1) the impact of maternal health and nutrition interventions on breast milk composition, and 2) its relation to infant health, growth and development. Each site will own its own data and will also be independently addressing these same questions by site, as originally intended in their own grants/studies. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
CHILD Study: observational study of healthy term infants from Canada, Multi-ethnic (~70% Caucasian; 30% others: Asian, First Nations, Black, other) ELICIT Study: factorial RCT study design, cohorts from Haydom, Tanzania, predominantly of Black and East African descent VITAL Study: 3-arm RCT study design, cohorts from Karachi, Pakistan, predominantly of Asian descent MISAMEIII Study: 2x2 cross-over RCT study design, cohorts from Hounde District, Burkina Faso, predominantly of Black and West African descent
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Meghan B Azad | University of Manitoba, CHILD Cohort Study | Principal Investigator |
| Estomih Mduma | Haydom Lutheran Hospital, ELICIT Trial | Study Director |
| Fyezah Jehan | Aga Khan University Pakistan, VITAL Trial | Principal Investigator |
| Laeticia Celine Toe | Institut de Recherche en Science de la Santa, MISAMEIII Trial | Study Director |
| PJ Subbarao | SickKids, CHILD Study | Study Director |
| Yasir Shafiq | Aga Khan University Pakistan, VITAL Trial | Principal Investigator |
| Mark D DeBoer | University of Virginia, VITAL Trial | Principal Investigator |
| Patrick Kolsteren | Ghent University, MISAMEIII Trial | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Manitoba Interdisciplinary Lactation Centre (MILC) | Winnipeg | Manitoba | R3E3P4 | Canada |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26375355 | Background | Andreas NJ, Kampmann B, Mehring Le-Doare K. Human breast milk: A review on its composition and bioactivity. Early Hum Dev. 2015 Nov;91(11):629-35. doi: 10.1016/j.earlhumdev.2015.08.013. Epub 2015 Sep 12. | |
| 23178060 | Background | Ballard O, Morrow AL. Human milk composition: nutrients and bioactive factors. Pediatr Clin North Am. 2013 Feb;60(1):49-74. doi: 10.1016/j.pcl.2012.10.002. |
Not provided
Not provided
Data to be shared: final, annotated datasets and associated documentation (protocols, questionnaires, codebooks, data dictionaries, etc.). Data will be deposited into an open access data repository.
Embargo period of 12 months followed by full open access
Embargo period of 12 months followed by full open access
Not provided
Not provided
| ID | Term |
|---|---|
| D009536 | Niacinamide |
| D017963 | Azithromycin |
| ID | Term |
|---|---|
| D009539 | Nicotinic Acids |
| D000147 | Acids, Heterocyclic |
| D006571 | Heterocyclic Compounds |
| D011725 | Pyridines |
Not provided
Not provided
| OTHER |
| Ludwig-Maximilians - University of Munich | OTHER |
| Johns Hopkins University | OTHER |
| Cedars-Sinai Medical Center | OTHER |
| Sapient Bioanalytics | UNKNOWN |
| University of California, Davis | OTHER |
| University of California, San Diego | OTHER |
| University of Virginia | OTHER |
| Aga Khan University | OTHER |
| University Ghent | OTHER |
| University of California, Berkeley | OTHER |
| University Health Network, Toronto | OTHER |
| USDA Beltsville Human Nutrition Research Center | FED |
| Antigen Discovery Inc | UNKNOWN |
| USDA, Western Human Nutrition Research Center | FED |
Not provided
Not provided
Not provided
Human Breast Milk Samples
| Micronutriments pour la Santé de la Mère et de l'Enfant (MISAME)-3 study (NCT03533712) | MISAME-3 is a randomized controlled clinical trial in the setting of Rural Burkina Faso. A BEP supplement provides less than 25% of protein of the total energy content, and includes different vitamins and minerals. The first part of an exploratory study will determine which type of BEP supplement (bar, drink, biscuit, soup or paste) is most accepted by pregnant women. Subsequently, two products will be tested for longer-term acceptability and at-home use (phase 1). The effect of the most suitable supplement will be tested in a controlled clinical trial (phase 2). The intervention group will receive the dietary supplement during pregnancy and/or lactation, while the control group complies with the standard iron and folic acid tablets following the national guidelines. IMiC will receive 600 breast milk samples from 200 dyads, 3 samples per dyad taken at 0-1, 1-2 & 3-4 months. |
|
|
| Azithromycin | Biological | ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants. VITAL Pakistan Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant. |
|
| Fortified food supplement | Dietary Supplement | VITAL Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant. MISAMEIII Study: 2x2 cross-over efficacy RCT of fortified food supplement (folic acid/iron +/- peanut spread) during pregnancy and/or lactation; unmasked (open label). |
|
Create an integrated analysis of this dataset, addressing research questions such as:
| This outcome is anticipated to reach completion in October 2023. |
| This outcome is anticipated to reach completion in October 2023. |
| 22513036 | Background | Bode L. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology. 2012 Sep;22(9):1147-62. doi: 10.1093/glycob/cws074. Epub 2012 Apr 18. |
| 30247646 | Background | Azad MB, Robertson B, Atakora F, Becker AB, Subbarao P, Moraes TJ, Mandhane PJ, Turvey SE, Lefebvre DL, Sears MR, Bode L. Human Milk Oligosaccharide Concentrations Are Associated with Multiple Fixed and Modifiable Maternal Characteristics, Environmental Factors, and Feeding Practices. J Nutr. 2018 Nov 1;148(11):1733-1742. doi: 10.1093/jn/nxy175. |
| 24500153 | Background | Innis SM. Impact of maternal diet on human milk composition and neurological development of infants. Am J Clin Nutr. 2014 Mar;99(3):734S-41S. doi: 10.3945/ajcn.113.072595. Epub 2014 Feb 5. |
| 29846526 | Background | Dror DK, Allen LH. Overview of Nutrients in Human Milk. Adv Nutr. 2018 May 1;9(suppl_1):278S-294S. doi: 10.1093/advances/nmy022. |
| 30723472 | Background | Dawod B, Marshall JS. Cytokines and Soluble Receptors in Breast Milk as Enhancers of Oral Tolerance Development. Front Immunol. 2019 Jan 22;10:16. doi: 10.3389/fimmu.2019.00016. eCollection 2019. |
| 20105664 | Background | Garofalo R. Cytokines in human milk. J Pediatr. 2010 Feb;156(2 Suppl):S36-40. doi: 10.1016/j.jpeds.2009.11.019. |
| 28788066 | Background | Demmelmair H, Prell C, Timby N, Lonnerdal B. Benefits of Lactoferrin, Osteopontin and Milk Fat Globule Membranes for Infants. Nutrients. 2017 Jul 28;9(8):817. doi: 10.3390/nu9080817. |
| 27504516 | Background | Jiang R, Lonnerdal B. Biological roles of milk osteopontin. Curr Opin Clin Nutr Metab Care. 2016 May;19(3):214-9. |
| 28925410 | Background | Chan D, Goruk S, Becker AB, Subbarao P, Mandhane PJ, Turvey SE, Lefebvre D, Sears MR, Field CJ, Azad MB. Adiponectin, leptin and insulin in breast milk: associations with maternal characteristics and infant body composition in the first year of life. Int J Obes (Lond). 2018 Jan;42(1):36-43. doi: 10.1038/ijo.2017.189. Epub 2017 Aug 14. |
| 28513622 | Background | Young BE, Patinkin Z, Palmer C, de la Houssaye B, Barbour LA, Hernandez T, Friedman JE, Krebs NF. Human milk insulin is related to maternal plasma insulin and BMI: but other components of human milk do not differ by BMI. Eur J Clin Nutr. 2017 Sep;71(9):1094-1100. doi: 10.1038/ejcn.2017.75. Epub 2017 May 17. |
| 30140664 | Background | Moossavi S, Miliku K, Sepehri S, Khafipour E, Azad MB. The Prebiotic and Probiotic Properties of Human Milk: Implications for Infant Immune Development and Pediatric Asthma. Front Pediatr. 2018 Jul 24;6:197. doi: 10.3389/fped.2018.00197. eCollection 2018. |
| 24913838 | Background | Musilova S, Rada V, Vlkova E, Bunesova V. Beneficial effects of human milk oligosaccharides on gut microbiota. Benef Microbes. 2014 Sep;5(3):273-83. doi: 10.3920/BM2013.0080. |
| 22585926 | Background | Wang B. Molecular mechanism underlying sialic acid as an essential nutrient for brain development and cognition. Adv Nutr. 2012 May 1;3(3):465S-72S. doi: 10.3945/an.112.001875. |
| 27940404 | Background | McGuire MK, McGuire MA. Got bacteria? The astounding, yet not-so-surprising, microbiome of human milk. Curr Opin Biotechnol. 2017 Apr;44:63-68. doi: 10.1016/j.copbio.2016.11.013. Epub 2016 Dec 8. |
| 31293535 | Background | Ruiz L, Garcia-Carral C, Rodriguez JM. Unfolding the Human Milk Microbiome Landscape in the Omics Era. Front Microbiol. 2019 Jun 25;10:1378. doi: 10.3389/fmicb.2019.01378. eCollection 2019. |
| 31025880 | Background | Togo A, Dufour JC, Lagier JC, Dubourg G, Raoult D, Million M. Repertoire of human breast and milk microbiota: a systematic review. Future Microbiol. 2019 May;14:623-641. doi: 10.2217/fmb-2018-0317. Epub 2019 Apr 26. |
| 30763539 | Background | Moossavi S, Sepehri S, Robertson B, Bode L, Goruk S, Field CJ, Lix LM, de Souza RJ, Becker AB, Mandhane PJ, Turvey SE, Subbarao P, Moraes TJ, Lefebvre DL, Sears MR, Khafipour E, Azad MB. Composition and Variation of the Human Milk Microbiota Are Influenced by Maternal and Early-Life Factors. Cell Host Microbe. 2019 Feb 13;25(2):324-335.e4. doi: 10.1016/j.chom.2019.01.011. |
| 28144631 | Background | Asnicar F, Manara S, Zolfo M, Truong DT, Scholz M, Armanini F, Ferretti P, Gorfer V, Pedrotti A, Tett A, Segata N. Studying Vertical Microbiome Transmission from Mothers to Infants by Strain-Level Metagenomic Profiling. mSystems. 2017 Jan 17;2(1):e00164-16. doi: 10.1128/mSystems.00164-16. eCollection 2017 Jan-Feb. |
| 28713343 | Background | Biagi E, Quercia S, Aceti A, Beghetti I, Rampelli S, Turroni S, Faldella G, Candela M, Brigidi P, Corvaglia L. The Bacterial Ecosystem of Mother's Milk and Infant's Mouth and Gut. Front Microbiol. 2017 Jun 30;8:1214. doi: 10.3389/fmicb.2017.01214. eCollection 2017. |
| 27339978 | Background | Blanton LV, Barratt MJ, Charbonneau MR, Ahmed T, Gordon JI. Childhood undernutrition, the gut microbiota, and microbiota-directed therapeutics. Science. 2016 Jun 24;352(6293):1533. doi: 10.1126/science.aad9359. |
| 31296738 | Background | Gehrig JL, Venkatesh S, Chang HW, Hibberd MC, Kung VL, Cheng J, Chen RY, Subramanian S, Cowardin CA, Meier MF, O'Donnell D, Talcott M, Spears LD, Semenkovich CF, Henrissat B, Giannone RJ, Hettich RL, Ilkayeva O, Muehlbauer M, Newgard CB, Sawyer C, Head RD, Rodionov DA, Arzamasov AA, Leyn SA, Osterman AL, Hossain MI, Islam M, Choudhury N, Sarker SA, Huq S, Mahmud I, Mostafa I, Mahfuz M, Barratt MJ, Ahmed T, Gordon JI. Effects of microbiota-directed foods in gnotobiotic animals and undernourished children. Science. 2019 Jul 12;365(6449):eaau4732. doi: 10.1126/science.aau4732. |
| 24896187 | Background | Subramanian S, Huq S, Yatsunenko T, Haque R, Mahfuz M, Alam MA, Benezra A, DeStefano J, Meier MF, Muegge BD, Barratt MJ, VanArendonk LG, Zhang Q, Province MA, Petri WA Jr, Ahmed T, Gordon JI. Persistent gut microbiota immaturity in malnourished Bangladeshi children. Nature. 2014 Jun 19;510(7505):417-21. doi: 10.1038/nature13421. Epub 2014 Jun 4. |
| 30994344 | Background | Foroutan A, Guo AC, Vazquez-Fresno R, Lipfert M, Zhang L, Zheng J, Badran H, Budinski Z, Mandal R, Ametaj BN, Wishart DS. Chemical Composition of Commercial Cow's Milk. J Agric Food Chem. 2019 May 1;67(17):4897-4914. doi: 10.1021/acs.jafc.9b00204. Epub 2019 Apr 17. |
| 40557242 | Derived | Fehr K, Mertens A, Shu CH, Dailey-Chwalibog T, Shenhav L, Allen LH, Beggs MR, Bode L, Chooniedass R, DeBoer MD, Deng L, Espinosa C, Hampel D, Jahual A, Jehan F, Jain M, Kolsteren P, Kawle P, Lagerborg KA, Manus MB, Mataraso S, McDermid JM, Muhammad A, Peymani P, Pham M, Shahab-Ferdows S, Shafiq Y, Subramoney V, Sunko D, Toe LC, Turvey SE, Xue L, Rodriguez N, Hubbard A, Aghaeepour N, Azad MB. Protocol: the International Milk Composition (IMiC) Consortium - a harmonized secondary analysis of human milk from four studies. Front Nutr. 2025 Jun 10;12:1548739. doi: 10.3389/fnut.2025.1548739. eCollection 2025. |
| D006573 |
| Heterocyclic Compounds, 1-Ring |
| D004917 | Erythromycin |
| D018942 | Macrolides |
| D061065 | Polyketides |
| D007783 | Lactones |
| D009930 | Organic Chemicals |